Equities Analysts Offer Predictions for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for ARS Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($1.21) per share for the year, down from their prior estimate of ($1.02). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million.

Several other equities analysts have also recently commented on SPRY. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective on the stock. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price for the company. Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Raymond James upped their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $31.00.

ARS Pharmaceuticals Price Performance

SPRY opened at $12.60 on Wednesday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -24.71 and a beta of 1.03. ARS Pharmaceuticals has a one year low of $7.55 and a one year high of $18.51. The company has a fifty day moving average price of $12.14 and a 200-day moving average price of $13.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SPRY. Connor Clark & Lunn Investment Management Ltd. bought a new stake in ARS Pharmaceuticals during the 3rd quarter valued at $1,120,000. Intech Investment Management LLC bought a new position in shares of ARS Pharmaceuticals during the third quarter valued at about $239,000. Charles Schwab Investment Management Inc. raised its stake in shares of ARS Pharmaceuticals by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 423,947 shares of the company’s stock valued at $6,147,000 after acquiring an additional 8,417 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of ARS Pharmaceuticals by 121.1% during the third quarter. The Manufacturers Life Insurance Company now owns 46,854 shares of the company’s stock worth $679,000 after purchasing an additional 25,658 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of ARS Pharmaceuticals by 766.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after purchasing an additional 207,456 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 7,696 shares in the company, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 159,600 shares of company stock worth $1,866,516. 40.10% of the stock is currently owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.